DEcompressive Surgery for the Treatment of malignant INfarction of the middle cerebral arterY - Registry (DESTINY-R): design and protocols by Hermann Neugebauer et al.
Neugebauer et al. BMC Neurology 2012, 12:115
http://www.biomedcentral.com/1471-2377/12/115STUDY PROTOCOL Open AccessDEcompressive Surgery for the Treatment of
malignant INfarction of the middle cerebral
arterY - Registry (DESTINY-R): design and protocols
Hermann Neugebauer1*, Peter U Heuschmann2 and Eric Jüttler1Abstract
Background: Randomized controlled trials (RCT) on the treatment of severe space-occupying infarction of the
middle cerebral artery (malignant MCA infarction) showed that early decompressive hemicraniectomy (DHC) is life
saving and improves outcome without promoting most severe disablity in patients aged 18–60 years. It is, however,
unknown whether the results obtained in the randomized trials are reproducible in a broader population in and
apart from an academical setting and whether hemicraniectomy has been implemented in clinical practice as
recommended by national and international guidelines. In addition, they were not powered to answer further
relevant questions, e.g. concerning the selection of patients eligible for and the timing of hemicraniectomy. Other
important issues such as the acceptance of disability following hemicraniectomy, the existence of specific
prognostic factors, the value of conservative therapeutic measures, and the overall complication rate related to
hemicraniectomy have not been sufficiently studied yet.
Methods/Design: DESTINY-R is a prospective, multicenter, open, controlled registry including a 12 months
follow-up. The only inclusion criteria is unilateral ischemic MCA stroke affecting more than 50% of the
MCA-territory. The primary study hypothesis is to confirm the results of the RCT (76% mRS≤ 4 after 12 months) in
the subgroup of patients additionally fulfilling the inclusion cirteria of the RCT in daily routine. Assuming a
calculated proportion of 0.76 for successes and a sample size of 300 for this subgroup, the width of the 95% CI,
calculated using Wilson's method, will be 0.096 with the lower bound 0.709 and the upper bound 0.805.
Discussion: The results of this study will provide information about the effectiveness of DHC in malignant MCA
infarction in a broad population and a real-life situation in addition to and beyond RCT. Further prospectively
obtained data will give crucial information on open questions and will be helpful in the plannig of upcomming
treatment studies.
Trial registration: (ICTRP and DRKS): DRKS00000624
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Severe space-occupying middle cerebral artery infarction
(malignant MCA infarction) is a worst case scenario in
stroke medicine. Comparable to other devastating sub-
types of stroke such as severe intracranial hemorrhage
and basilar artery thrombosis therapeutic options are
limited and questionable with respect to improved* Correspondence: Hermann.Neugebauer@charite.de
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distribution, and reproduction in any mediumoutcome. Even under maximum intensive care treatment
most patients die after only few days due to relentless
edema formation, brain tissue shift and transtentorial
herniation [1-3]. In contrast, decompressive hemicra-
niectomy (DHC) has been proven a life saving surgical
intervention. Its efficacy in malignant MCA infarction
has been demonstrated in three randomized controlled
trials (RCT), their a pooled-analysis, and a recent meta-
analysis: Early DHC within 48 hours significantly
reduces mortality and improves the chance of survivingntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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risk of most severe disability [4-7].
Although the RCT and the two analyses gave answer
to the most pertinent question, they were not powered
for other important issues: First, due to the strict inclu-
sion criteria of the RCT, only healthy and independent
young patients (18–60 years) were treated. In addition, a
positive treatment effect was only found within 48 hours
after stroke onset [4-7]. Therefore, it is unclear if the
results can be extrapolated to real world situations,
when co-morbidities and dependency are common and
the decision to proceed with decompressive surgery
is made later on in the course of the disease. Second,
since the RCT were not powered for adequate subgroup
analysis - only 109 patients were included in the latest
meta-analysis, 58 underwent DHC and 51 were treated
conservatively [4]- it remains unclear which individual
patients benefit from surgical decompression, e.g. with res-
pect to age, presence of aphasia, and timing of surgical
intervention. Moreover, it remains unclear which clinical
or radiolgical factors sufficiently predict edema formation
and thus allow selection of patients for DHC in advance of
clinical deterioration [8-12]. Third, with respect to the ex-
tent of the infarction and the unrealistic expectation of
complete recovery after severe stroke, “favorable” outcome
was defined as a score of≤4 on the modified Rankin scale
(mRS) in the pooled-analysis of the RCT [7]. It is a matter
of ongoing debate amongst experts if such a condition
may be classified as “favorable”[13]. Indeed, some authors
and the latest meta-analysis defined favorable as a mRS
of≤3 [4]. Other authors think that the question of favor-
able (or in such severe diseases rather “acceptable”) out-
come should be answered by the patients themselves.
Unfortunately, the contradictory data on quality of life and
retrospective consent to hemicraniectomy after malignant
MCA infarction that are currently found in the literature
are of little help in preoperative decision making [5,9,14-
18]. Fourth, the actual effectiveness of conservative treat-
ment has never been addressed in detail, e.g. the RCT
showed different outcomes in the conservative treatment
groups: patients who were treated on an intensive care
unit [5] had a higher rate of survival (47% vs. 22%) and
more often better functional outcome (mRS 0–4: 33% vs.
0%) than patients treated on a stroke unit or a general
ward [6]. Fifth, despite the life-saving character of DHC,
the overall case fatality rate in patients who underwent
surgery in the RCT was still 29% [7]. This means that
nearly every third patient dies for reasons not well under-
stood. Similarly, no valid data are available on the actual
rate of complications especially concerning re-implantation
of the skull.
Most of these issues are a commonplace in the scien-
tific community and have been addressed in a number
of case series and non-randomized case control studies[19-21]. However, most of these studies are retrospective
in nature, lack appropriate control groups, and show
heterogeneous or inconclusive results. Therefore, proper
investigation in a large-size, prospective study is urgently
needed. Besides, the implementation of hemicraniect-
omy in clinical practice has not been reviewed since the
publication of the RCT.
Methods
Study design
DESTINY-R is a prospective, multicenter, open, and
controlled registry. There will be no active allocation of
the patients either to hemicraniectomy or any conserva-
tive treatment option. At the time of publication 45
neurologic and neurosurgical departments were regis-
tered as actively recruiting study centers. All participat-
ing centers have adequate experience with the
management of acute ischemic stroke, intensive care
treatment of patients with increased intracranial pres-
sure (ICP) and access to neurosurgical facilities on a 24-
hours/day basis.
Ethics
The study protocol and all subsequent amendments are
approved by the leading ethic committee of the Charité-
Universitätsmedizin Berlin (Ethic Committee at Campus
Benjamin Franklin, Reference number EA4/108/109,
date of approval 12/08/09) and the local ethics commit-
tees of the participating centers. The study is performed
in accordance with the Declaration of Helsinki and its
subsequent amendments, as well as the guidelines of
Good Clinical Practice. The study is registered at the
German Clinical Trial Register (DRKS) and the Inter-
national Clinical Trials Registry Platform (ICTRP). The
registration number is DRKS00000624. Written
informed consent is obtained from subjects who meet
the study inclusion criteria or their legal representatives,
respectively.
Study subject recruitment
At each study site patients older than 18 years of age are
screened and asked for participation if they meet the fol-
lowing inclusion criteria: (a) clinical signs of unilateral
MCA infarction, (b) ischemic infarction affecting at least
50% of the MCA territory confirmed by computed tom-
ography (CT) or magnetic resonance imaging (MRI).
Additional involvement of the anterior and/or posterior
cerebral artery territories may be present, (c) written
informed consent of the patient or their legal representa-
tive. Because treatment is independent from participa-
tion in DESTINY-R there is no time interval for
inclusion. The only exclusion criterion is a simultaneous
or contemporary acute brain injury, e.g. traumatic brain
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tentorial in addition to the index- infarction.
Study protocol
After written informed consent is obtained patients are
enrolled in the study and baseline data are documented
(visit 1). Subsequently, patient’s medical treatment data
are recorded throughout the regular treatment. No add-
itional examinations or interventions are carried out by
reasons of the study. At discharge medical treatment
data are documented in the case-report-form (visit 2).
One year after symptom onset patients or their legal
representatives are contacted by phone or letter (visit 3).
Follow-up data are also documented in the CRF. After
completion a copy of the CRF and a compact disc con-
taining the patients’ pseudonymized neuroimaging data
is sent to the coordinating center (Center for Stroke Re-
search Berlin (CSB)), which is responsible for data man-
agement and analysis.
Data collection
Baseline documentation of clinical data includes demo-
graphic factors, past medical history, history of present
illness, and the previous functional status measured on
the mRS and NIHSS. Imaging data includes infarct
localization, presence of space-occupying edema, and
hemorrhagic transformation. Considering conservative
treatment measures, the use of ICP-lowering drugs, and
data on sedation, muscle relaxation and mechanical ven-
tilation will be recorded. With respect to surgical proce-
dures, the time-to-surgery, the diameter of craniotomy,
and the type of duraplasty will be recorded. Complica-
tions during the initial hospital stay will also be
recorded. At follow-up, data acquisition is done using a
structured interview including the modified Rankin
Scale, the Barthel-Index, the EuroQoL-5D, the SF-36,
and the Hamilton Depression Rating Scale (HDRS). Fur-
thermore, complications during the follow-up period
and, if applicable, the retrospective consent to treatment
will be recorded.
Outcome measures
The primary outcome measure is functional outcome as
determined by the mRS score, dichotomized between
0–4 and 5 or 6 at 1 year ± 14 days after symptom onset
in the subgroup of patients additionally fulfilling the in-
clusion criteria of the RCT. Secondary outcome mea-
sures are: (a) mortality, (b) median time of survival
assessed by the Kaplan-Meier estimator, (c) functional
outcome as determined by the mRS Score dichotomized
between 0–3 and 4–6 at 1 year ± 14 days after symptom
onset, (d) treatment modes (i.e. osmotherapy, hyperven-
tilation, sedation, etc.), assessed at discharge if applic-
able, time to decompressive surgery, diameter of boneflap/craniectomy measured in situ and by neuroimaging,
type of duraplasty, if applicable, as well as complications
(i.e. hygroma, impaired wound healing, epidural and sub-
dural hematoma, parenchymatous hematoma, wound and
bone flap infections) and (f) time to cranioplasty assessed
1 year ± 14 days after symptom onset if applicable, other
complications (i.e. pneumonia, and any other infection,
thrombosis, seizures), (g) quality of life determinded by
the SF-36 and EuroQoL-5D questionnaires and depression
assessed by the HDRS, and (h) rate of retrospective con-
sent to treatment assessed 1 year ± 14 days after symptom
onset.Sample size calculation
Assuming a calculated proportion of 0.76 for successes
in the subgroup of patients additionally fulfilling the in-
clusion cirteria of the RCT, and a sample size of 300 for
this subgroup, the width of the 95% CI, calculated using
Wilson's method, will be 0.096 with the lower bound
0.709 and the upper bound 0.805 [22]. Given an esti-
mated enrolement of 4 patients per center/year at 45
study centers plus one year of follow-up, data acquisition
would be concluded in 3 years. Thus the end of the
study is planned for 2014.Data analysis
All outcome measures will undergo descriptive data ana-
lysis, including mean, standard deviation, median, range,
as well as absolute and relative frequencies depending
on the scales of the variables. Additionally, descriptive
p-values for group comparison and the corresponding
95% confidence interval will be indicated. Two-sample t
testing, the Mann–Whitney U-test, or χ2-testing will be
used to analyze group differences as applicable. Kaplan-
Meier estimates and log-rank statistics will be used for
assessing cumulative risk of death at 12 months. The
comparability of different treatment groups will be
depicted by comparing demographic and baseline data.
Statistical analysis will be performed using the latest
SAS software version (SAS Institute Inc., Cary, NC).Monitoring
Internal and external audits will be held in order to assure
quality standards according to the Declaration of Hel-
sinki, ICH-GCP guidelines, and governmental standards.Publication of the trial results
The trial results will be published independently of the
results by the members of the Steering Committee and
the participating centers (DESTINY-R study group).
Authorship as well as publication of partial results will
be regulated by the Steering Committee.
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We advocate the use of a prospective register to further
characterize patients with malignant MCA infarction
and evaluate implementation, effectiveness and adverse
events of current treatment concepts, including DHC.
Although first trends in prevalence and outcome of
DHC are promising and seem comparable to the results
of the RCT [23,24], the use of a large database allows
the representation of a much broader population of
patients treated for malignant MCA infarction. The
anticipated sample size should allow confirming the
results of the RCT and raising new hypotheses even if
the population turns out to be more heterogeneous than
expected. The planned inclusion of at least 300 patients
in a reasonable time frame can only be achieved in a
multicenter approach. The open design allows continu-
ing initiation of cooperative study centers. The very con-
servative estimate of 4 patients/year per center would
probably allow extending patient recruitment to 500 or
even 1000 if certain questions would need a larger sam-
ple size to be investigated. However, due to the nature of
a prospective registry, only hypotheses may be created,
which then need further investigation in RCT.
To avoid the investigation of a very restricted group of
patients, the inclusion criterion of infarct size was
intentionally set comparatively wide. Thus any patient
with a MCA infarction involving more than 50% of the
territory can be included irrespective of treatment, al-
though eligibility criteria for the RCT were infarction of
more than 2/3 of the MCA territory. However, as the in-
dividual factors promoting infarct swelling are not well
understood yet, not considering these patients may pos-
sibly exclude a subgroup of patients that would have the
potential to benefit from a certain treatment option in
the future. The limited number of eligibility criteria are
easy to implement even in small hospitals with limited
staff and will most likely result in a patient mix repre-
sentative of clinical practice. Conservatively treated
patients are followed simultaneously and constitute the
control group, which may be compared to surgically
treated patients in this parallel design. Due to treatment
bias it may be possible that treatment groups show sig-
nificantly different baseline data making a true compari-
son difficult. The expected number of patients should,
however, be large enough to compensate for lower event
rates or differences in baseline data.
The primary outcome measure is functional outcome
after 1 year determined by the mRS score and dichoto-
mized between 0–4 versus 5–6. This endpoint was
chosen to ensure comparability with the results of the
pooled analysis of the RCT. Secondary outcome mea-
sures were chosen following the aforementioned open
questions that could not be answered in the RCT or
have not been conclusively answered in clinical studiesyet. They furthermore allow subgroup analyses, e.g. eld-
erly patients, dominant-hemispheric infarction, and tim-
ing of treatment, some of which are currently under
investigation in accompanying studies [25].
The assessment of prognostic factors will lead to a bet-
ter understanding of the risk of malignant infarct swel-
ling and will aid clinical decision-making. We do not
claim to assess causative associations in a cohort study.
However, we expect to find predictive associations that
will be of value in the immediate treatment process as
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